Clinical Scorecard: Triple-positive profile may flag adverse prostate cancer pathology
At a Glance
| Category | Detail |
|---|---|
| Condition | Prostate Cancer |
| Key Mechanisms | Combination of prostate-specific antigen density, multiparametric MRI, and PSMA PET/CT findings |
| Target Population | Patients undergoing radical prostatectomy for prostate cancer |
| Care Setting | Retrospective evaluation in a single-center study |
Key Highlights
- 60% of patients had adverse pathology at radical prostatectomy.
- Adverse pathology rates increased with higher PSAD and PI-RADS scores.
- The triple-positive profile showed 100% specificity and positive predictive value.
- Only 22 patients met all three criteria for the triple-positive profile.
- The study suggests further investigation into biopsy-sparing strategies.
Guideline-Based Recommendations
Diagnosis
- Evaluate prostate-specific antigen density, mpMRI, and PSMA PET/CT findings.
Management
- Consider the triple-positive profile for prospective studies of biopsy omission.
Monitoring & Follow-up
- Monitor patients with PSAD, PI-RADS, and SUVmax findings.
Risks
- Potential for selection bias and unmeasured confounding due to retrospective design.
Patient & Prescribing Data
413 patients who underwent radical prostatectomy between December 2015 and December 2024.
Biopsy provides important histologic information for treatment planning.
Clinical Best Practices
- Use combined clinical and imaging predictors for assessing adverse pathology.
- External validation of proposed criteria is warranted before adoption.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
